EASL- and mRECIST-Evaluated Responses to Combination Therapy of Sorafenib with Transarterial Chemoembolization Predict Survival in Patients with Hepatocellular Carcinoma

Clinical Cancer Research

Volumn 20, Issue 6, 2014, Pages 1623-1631

  Liu, Lei ^a   Wang, Weijuan ^a   Chen, Hui ^a   Zhao, Yan ^a   Bai, Wei ^a   Yin, Zhanxin ^a   He, Chuangye ^a   Jia, Jia ^a   Yang, Man ^a   Xia, Jielai ^b   Fan, Daiming ^a   Han, Guohong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Medical Statistics ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN; SORAFENIB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER CRITERIA; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; RETROSPECTIVE STUDY; RISK REDUCTION; CARCINOMA, HEPATOCELLULAR; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84896520324     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1716     Document Type: Article

References (29)

1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90.
3. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
4. Eisenhauer EA. Response evaluation: beyond RECIST. Ann Oncol 2007;18 (suppl):ix29-ix32.
5. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006;6: 409-14.
6. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, Reig M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115:616-23.
7. Keppke AL, Salem R, Reddy D, Huang J, Jin J, Larson AC, et al. Imaging of hepatocellular carcinoma after treatment with Yttrium-90 microspheres. AJR 2007;188:768-75.
8. Duke E, Deng J, Ibrahim SM, Lewandoeski RJ, Ryu RK, Sato KT, et al. Agreement between competing imaging measures of response of hepatocellular carcinoma to Yttrium-90 radioembolization. J Vasc Interv Radiol 2010;21:515-21.
9. Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-60.
10. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
11. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35: 421-30.
12. Memon K, Kulik L, Lewandowski JL, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141: 526-35.
13. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation. J Hepatol 2011;55:1309-16.
14. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012;262:708-18.
15. Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012;118:147-56.
16. Spira D, Fenchel M, Lauer UM, Claussen CD, Gregor M, Bitzer M, et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 2011;18:89-96.
17. Dufour JF. TACE with or without systemic therapy? J Hepatol 2012; 56:1224-5.
18. Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 2010;15:1198-204.
19. Park JW, Koh Y, Kim H, Kim H, An S, Choi J-I, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib for patients with unresectable hepatocellular carcinoma. J Hepatol 2012;56: 1336-42.
20. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011;29:3960-7.
21. Zhao Y, Wang W, Guan S, Li H, Xu R, Wu J, et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol 2013;24:1786-92.
22. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
23. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
24. Altman D. Practical statistics for medical research. London, England: Chapman & Hall; 1991.
25. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008;26:3913-5.
26. Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, et al. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 2012;265:115-23.
27. Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010;303:1062-9.
28. Bruix J, Reig M, Rimola J, Forner A, Burrel M, Vilana R, et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 2011;54: 2238-44.
29. Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33:532-40.